17-OHPC to Prevent Recurrent Preterm Birth in Singleton Gestations (PROLONG Study)

Women with a history of spontaneous preterm birth (SPTB) are at a significantly increased risk for recurrent preterm birth (PTB). To date, only one large U.S. clinical trial comparing 17-OHPC (17-α-hydroxyprogesterone caproate or “17P”) to placebo has been published, and this trial was stopped early due to a large treatment benefit. This study aimed to assess whether 17-OHPC decreases recurrent PTB and neonatal morbidity in women with a prior SPTB in a singleton gestation. Click here to read the Full Text article:

17-P,17-HPC,17-OHPC,17-hydroxyprogesterone caproate,progestogens,preterm birth,recurrent preterm birth,spontaneous preterm birth,